Cytotoxic chemotherapy reduces T cell trafficking to the spleen by downregulating the expression of C‑C motif chemokine ligand 21 and C‑C motif chemokine ligand 19

Liu,Lina; Zhao,Lintao; Yang,Yang; Gao,Jianbao; Hu,Chunyan; Guo,Bo; Zhu,Bo

doi:10.3892/ol.2018.9287

Cytotoxic chemotherapy reduces T cell trafficking to the spleen by downregulating the expression of C‑C motif chemokine ligand 21 and C‑C motif chemokine ligand 19

Authors:
- Lina Liu
- Lintao Zhao
- Yang Yang
- Jianbao Gao
- Chunyan Hu
- Bo Guo
- Bo Zhu
View Affiliations

Affiliations: Institute of Oncology, Third Inpatient Building of Xinqiao Hospital, Third Military Medical University, Chongqing 400037, P.R. China, Department of Microbiology, Third Military Medical University, Chongqing 400037, P.R. China
Published online on: August 9, 2018 https://doi.org/10.3892/ol.2018.9287
Pages: 5013-5019
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

T cells serve an important role in the destruction of tumor cells and clearing of foreign pathogens. Previous studies have suggested that the T cell immune response of tumor‑bearing patients is significantly lower than that of healthy people, and the principal reason for this is lymphocytopenia, which is caused by repeated cycles of chemotherapy. In addition to lymphocytopenia, the present study revealed that cytotoxic chemotherapy also weakens the homing ability of T cells to the T‑cell zone of the spleen, which decreases the possibility of encounters between antigen‑specific T cells and dendritic cells presenting the appropriate antigen, thereby weakening the immune response of T cells. These changes are attributed to the lower expression of C‑C motif chemokine ligand 21 (CCL21) and C‑C motif chemokine ligand 19 (CCL19) in the spleen of secondary lymphoid organs (SLOs). Finally, the present study identified that chemotherapy affects the function and survival of fibroblastic reticular cells in SLOs, which are the main source of CCL21 and CCL19. These observations aid us in further understanding the mechanism that is responsible for the decreased T cell immune response following repeated cycles of chemotherapy.

View Figures

View References

1	Bodey GP: Infection in cancer patients. A continuing association. Am J Med. 81:11–26. 1986. View Article : Google Scholar : PubMed/NCBI
2	de Martel C and Franceschi S: Infections and cancer: Established associations and new hypotheses. Crit Rev Oncol Hematol. 70:183–194. 2009. View Article : Google Scholar : PubMed/NCBI
3	Foerster R, Davalos-Misslitz AC and Rot A: CCR7 and its ligands: Balancing immunity and tolerance. Nat Rev Immunol. 8:362–371. 2008. View Article : Google Scholar : PubMed/NCBI
4	Foerster R, Schubel A, Breitfeld D, Kremmer E, Renner-Müller I, Wolf E and Lipp M: CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell. 99:23–33. 1999. View Article : Google Scholar : PubMed/NCBI
5	Brandman JR, Ruckdeschel JC, O'Donnell MR and Horton J: Small cell cancer of lung; rapid tumor necrosis leading to serious pulmonary infections after intensive chemotherapy. NY State J Med. 81:1332–1334. 1981.
6	Vento S, Cainelli F and Ternesgen Z: Lung infections after cancer chemotherapy. Lancet Oncol. 9:982–992. 2008. View Article : Google Scholar : PubMed/NCBI
7	Vento S and Cainelli F: Infections in patients with cancer undergoing chemotherapy: Aetiology, prevention, and treatment. Lancet Oncol. 4:595–604. 2003. View Article : Google Scholar : PubMed/NCBI
8	De Visser KE, Schumacher TNM and Kruisbeek AM: CD8(+) T cell tolerance and cancer immunotherapy. J Immunother. 26:1–11. 2003. View Article : Google Scholar : PubMed/NCBI
9	Marchant A and Goldman M: T cell-mediated immune responses in human newborns: Ready to learn? Clin Exp Immunol. 141:10–18. 2005. View Article : Google Scholar : PubMed/NCBI
10	Day TA, Koch M, Nouailles G, Jacobsen M, Kosmiadi GA, Miekley D, Kuhlmann S, Jörg S, Gamradt P, Mollenkopf HJ, et al: Secondary lymphoid organs are dispensable for the development of T-cell-mediated immunity during tuberculosis. Eur J Immunol. 40:1663–1673. 2010. View Article : Google Scholar : PubMed/NCBI
11	Mueller SN, Hosiawa-Meagher KA, Konieczny BT, Sullivan BM, Bachmann MF, Locksley RM, Ahmed R and Matloubian M: Regulation of homeostatic chemokine expression and cell trafficking during immune responses. Science. 317:670–674. 2007. View Article : Google Scholar : PubMed/NCBI
12	Zhao L, Liu L, Guo B and Zhu B: Regulation of adaptive immune responses by guiding cell movements in the spleen. Frontiers Microbiol. 6:2015. View Article : Google Scholar
13	Siegert S and Luther SA: Positive and negative regulation of T cell responses by fibroblastic reticular cells within paracortical regions of lymph nodes. Front Immunol. 3:2852012. View Article : Google Scholar : PubMed/NCBI
14	Malhotra D, Fletcher AL, Astarita J, Lukacs-Kornek V, Tayalia P, Gonzalez SF, Elpek KG, Chang SK, Knoblich K, Hemler ME, et al: Transcriptional profiling of stroma from inflamed and resting lymph nodes defines immunological hallmarks. Nat Immunol. 13:499–510. 2012. View Article : Google Scholar : PubMed/NCBI
15	Cesta MF: Normal structure, function, and histology of the spleen. Toxicol Pathol. 34:455–465. 2006. View Article : Google Scholar : PubMed/NCBI
16	den Haan JM, Mebius RE and Kraal G: Stromal cells of the mouse spleen. Front Immunol. 3:2012012.PubMed/NCBI
17	Luther SA, Bidgol A, Hargreaves DC, Schmidt A, Xu Y, Paniyadi J, Matloubian M and Cyster JG: Differing activities of homeostatic chemokines CCL19, CCL21, and CXCL12 in lymphocyte and dendritic cell recruitment and lymphoid neogenesis. J Immunol. 169:424–433. 2002. View Article : Google Scholar : PubMed/NCBI
18	Bajenoff M, Egen JG, Koo LY, Laugier JP, Brau F, Glaichenhaus N and Germain RN: Stromal cell networks regulate lymphocyte entry, migration, and territoriality in lymph nodes. Immunity. 25:989–1001. 2006. View Article : Google Scholar : PubMed/NCBI
19	Bepler G, Kusmartseva I, Sharma S, Gautam A, Cantor A, Sharma A and Simon G: RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. J Clin Oncol. 24:4731–4737. 2006. View Article : Google Scholar : PubMed/NCBI
20	Barry MA, Behnke CA and Eastman A: Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia. Biochem Pharmacol. 40:2353–2362. 1990. View Article : Google Scholar : PubMed/NCBI
21	Vincent J, Mignot G, Chalmin F, Ladoire S, Bruchard M, Chevriaux A, Martin F, Apetoh L, Rébé C and Ghiringhelli F: 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res. 70:3052–3061. 2010. View Article : Google Scholar : PubMed/NCBI
22	Zhao L, Gao J, Li Y, Liu L, Yang Y, Guo B and Zhu B: Disrupted homeostatic cytokines expression in secondary lymph organs during HIV infection. Int J Mol Sci. 17:4132016. View Article : Google Scholar : PubMed/NCBI
23	Zhao L, Chen J, Liu L, Gao J, Guo B and Zhu B: Essential role of TNF-alpha in development of spleen fibroblastic reticular cells. Cell Immunol. 293:130–136. 2015. View Article : Google Scholar : PubMed/NCBI
24	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
25	Shitara K, Matsuo K, Oze I, Mizota A, Kondo C, Nomura M, Yokota T, Takahari D, Ura T and Muro K: Meta-analysis of neutropenia or leukopenia as a prognostic factor in patients with malignant disease undergoing chemotherapy. Cancer Chemother Pharmacol. 68:301–307. 2011. View Article : Google Scholar : PubMed/NCBI
26	Bruserud O, Bergheim J, Shammas FV and Nesthus I: Serum concentrations of tumour necrosis factor-alpha during chemotherapy-induced leukopenia in patients with acute leukaemia and bacterial infections. Leuk Res. 18:415–421. 1994. View Article : Google Scholar : PubMed/NCBI
27	De Togni P, Goellner J, Ruddle NH, Streeter PR, Fick A, Mariathasan S, Smith SC, Carison R, Shonnick LP, Strauss-Schoenberger J, et al: Abnormal development of peripheral lymphoid organs in mice deficient in lymphotoxin. Science. 264:703–707. 1994. View Article : Google Scholar : PubMed/NCBI
28	Stranford S and Ruddle NH: Follicular dendritic cells, conduits, lymphatic vessels, and high endothelial venules in tertiary lymphoid organs: Parallels with lymph node stroma. Frontiers Immunol. 3:3502012. View Article : Google Scholar
29	Bronte V and Pittet MJ: The spleen in local and systemic regulation of immunity. Immunity. 39:806–818. 2013. View Article : Google Scholar : PubMed/NCBI
30	Zhao L, Liu L, Gao J, Yang Y, Hu C, Guo B and Zhu B: T lymphocytes maintain structure and function of fibroblastic reticular cells via lymphotoxin (LT)-B. BMC Immunol. 15:33. 2014. View Article : Google Scholar : PubMed/NCBI
31	Malhotra D, Fletcher AL and Turley SJ: Stromal and hematopoietic cells in secondary lymphoid organs: Partners in immunity. Immunol Rev. 251:160–176. 2013. View Article : Google Scholar : PubMed/NCBI
32	Turley SJ, Fletcher AL and Elpek KG: The stromal and haematopoietic antigen-presenting cells that reside in secondary lymphoid organs. Nat Rev Immunol. 10:813–825. 2010. View Article : Google Scholar : PubMed/NCBI